Close this search box.

Financial Reporting Valuation Opinions

RNA built the foundation of its business on delivering valuation opinions for financial reporting purposes for life science companies.  From the accounting requirements of large purchase price allocations and licensing transactions to complex securities, derivative accounting and stock compensation issues, we’ve worked with literally 1000’s of private companies and 100’s of public companies (and many that have made the transition).  Our team not only is comprised of people with Big 4 and large valuation firm backgrounds but it also is comprised of experts who understand the industry. RNA Advisors provides financial reporting valuation opinions including but not limited to those around Business Combinations and Goodwill Impairment, Derivatives and Share-based Compensation, Revenue Recognition from Multi-Element Licensing Transactions, and Incremental Borrowing Rate (IBR) Analyses.


Highlighted Case Study

Exploring Multiple Strategic Options: A Multi-Track Process

Highlighted Case Study

Due Diligence Support (Buy-Side): Fund Manager

Highlighted Case Study

Supporting the Entire Life Cycle: Biotech Company

Highlighted Case Study

Portfolio Valuation: Life Sciences Investments

What Our Clients Say

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.